The News in Depth
Synthesis and Analysis Advancements Are Unleashing the Potential of Peptides and Oligos, Spurring CMC Regulatory Dialogue
Advancements in synthesis and analysis technologies are helping unleash the therapeutic potential of peptides and oligonucleotides, spurring the dialogue on how the CMC/quality regulatory expectations, guidance and standards should keep pace.
July 23, 2020 | Posted in The News in Depth | Read More »
USP Convention Meets Virtually in May 2020 to Review Upcoming Priorities, with Both 200-Year Legacy and Current Pandemic in Focus
In May 2020, the USP Convention (USPC) met virtually to review how its central role in advancing public health has evolved during the broad sweep of its 200-year history on the one hand, while assessing its response to the pressing needs of the COVID-19 crisis now dominating the healthcare field on the other.
July 16, 2020 | Posted in The News in Depth | Read More »
IPQ Monthly Update – April/May 2020 in Review
The need for intensive collaboration to address the complex challenges of assuring the quality and availability of the world’s medicines has only deepened in the face of the global pandemic we are now facing, as the two stories in our review of April and May make clear. ● The first story is a five-part exploration of the collaborative efforts now going on globally to advance in vitro testing in assessing and controlling adventitious viruses for vaccines and biotherapeutics – and to unleash the potential of next-gen sequencing in particular. ● The second story explores how the National Institute for Innovation in Manufacturing Biopharmaceuticals has been evolving and some of the challenges now drawing the attention of the public/private partnership.
July 8, 2020 | Posted in The News in Depth | Read More »
COVID-19 Vaccine Urgency Throws Spotlight on Next-Gen Sequencing for Virus Control
The urgency of delivering a vaccine for COVID-19 in previously unattainable timeframes and volumes is throwing the spotlight on the expanded role next-generation sequencing (NGS) needs to play to avoid the time delays and other limitations of in vivo/animal testing.
May 31, 2020 | Posted in The News in Depth | Read More »
NIIMBL Progress Includes Partnership with Biophorum on Buffer Mixing and Global Health Fund with Gates Foundation
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is partnering with the industry consortium BioPhorum to develop a more streamlined, cost-effective, and resource-conserving way of addressing the buffers used in biopharmaceutical manufacturing.
May 15, 2020 | Posted in The News in Depth | Read More »
IPQ Monthly Update – March 2020 in Review
The first story in the March Monthly Update explores recent FDA global field inspection and enforcement operations. In focus are: ● the impact of the pandemic ● the field office’s API and drug product inventory and enforcement tools ● recent warning letter and import alert data and trends, and ● progress on the goals of reducing the timelines for inspection classification/notification and warning letter issuance. The following story provides insights from FDA’s drug compliance management on the recent global developments and trends of significance across the API, OTC, sterile product, compounding, and supply chain arenas.
April 23, 2020 | Posted in The News in Depth | Read More »
Top FDA Drug Compliance Concerns during 2019 Included OTCs, Supply Chain Information Flow, Compounding, and Genotoxic Impurities
Over-the-counter (OTC) drugs – from raw material supply through product manufacturing and distribution – remained a central concern at the FDA Center for Drug Evaluation and Research (CDER) Office of Compliance (OC) during 2019.
April 16, 2020 | Posted in The News in Depth | Read More »
Existing Accelerated CMC, Advanced Manufacturing, and Inspection Initiatives are Supporting Regulators in Pandemic Response, FDA’s Cruse Explains in Recent Field Office Updates
Initiatives that the major regulatory agencies have been advancing to help address the CMC and technology challenges of developing complex medicines under accelerated timelines are creating a critical foundation for responding to the current coronavirus pandemic.
April 7, 2020 | Posted in The News in Depth | Read More »
